Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • When typing in this field, a list of search results will appear and be automatically updated as you type.

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

InMode Announces New Share Repurchase Program

InMode Logo (PRNewsfoto/InMode)

News provided by

InMode Ltd.

13 Mar, 2026, 13:00 IST

Share this article

Share toX

Share this article

Share toX

YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the Company's total shares outstanding, representing approximately 6.38 million ordinary shares.

In 2025, the Company repurchased approximately $127.4 million of its outstanding ordinary shares through share repurchase programs. Despite a challenging macroeconomic environment, the Company continues to generate strong cash flow and believes that repurchasing shares at its current valuation represents an attractive use of capital.

While management remains focused on navigating the ongoing regional conflict and maintaining a disciplined approach to capital allocation, the Company will continue to evaluate additional share repurchase programs and other capital allocation opportunities going forward.

The Company expects to fund repurchases under the program with available cash. Repurchases may be made from time to time in the open market or through other permitted means, subject to market conditions and applicable legal requirements. The program may be modified, suspended, or discontinued at any time at the Company's discretion.

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com/.

Forward-Looking Statements

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the actual amount of share repurchases made by the Company, if any. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2026, and our subsequent public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

Company Contact:

Yair Malca

Chief Financial Officer

Phone: (949) 305-0108

Email: [email protected]

Investor Relations Contact      

Miri Segal

MS-IR LLC

Email: [email protected]

Logo - https://mma.prnewswire.com/media/1064477/5862039/InMode_Logo.jpg

SOURCE InMode Ltd.

Modal title

Also from this source

InMode Announces Conclusion of Independent Transaction Committee Review

InMode Announces Conclusion of Independent Transaction Committee Review

InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today announced that the...

InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million

InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million

InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Medical Equipment

Medical Equipment

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2026 Cision US Inc.